Rare diseases get the spotlight on “Behind The Mystery – Rare and Genetic Diseases;” special episodes of The Balancing Act, which airs on Lifetime weekday mornings at 7AM.
The mission of “Behind the Mystery: Rare and Genetic Diseases” is to educate the public about rare and genetic diseases and treatments, and provide support through collaborations in education with pharmaceutical companies, foundations and patient advocacy groups. Partnering with the Global Genes Project, The Balancing Act is the only television show with a special of this kind, working to bring awareness to the plight of rare disease sufferers and the quest for FDA approved treatments and therapies.
The Balancing Act is currently looking for: people from pharmaceutical companies doing research, or working on drug therapies for any of the many rare diseases out there; advocates or representatives from various rare disease group; people who are part of the rare disease world to continue with the series and its mission to be a place when people in the rare disease community can gather for more information.
The special airs every few weeks, past specials are available for viewing here: http://www.thebalancingact.com/rare/
If you’d like to get involved, please contact:
Carri Levy
Senior Associate Producer
The Balancing Act
[email protected]
Related Links:
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.